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High Incidence of Glucose-6-phosphate Dehydrogenase Deficiency in 
Croatian Island Isolate: Example from Vis Island, Croatia
Aim To determine the prevalence of glucose-6-phosphate dehy-
drogenase (G6PD) deficiency in the population of the town of 
Komiža on the island of Vis, which has previously been reported 
as a place with several cases of favism.
Methods We screened 302 randomly selected men, using the 
fluorescent spot test. Fluorescence readings were performed at 
the beginning and 5, 10, and 20 minutes after incubation, and 
were classified into three groups: bright fluorescence, weak fluo-
rescence, and no fluorescence. All men found to be G6PD de-
ficient were tested with a quantitative spectrophotometric UV 
method.
Results Of the 302 tested blood samples, 36 (11.9%) samples 
showed weak fluorescence or no fluorescence spots. Spectropho-
tometric UV test showed that 18 (5.96%) men were G6PD de-
ficient. The prevalence of G6PD deficiency in the population of 
Komiža is significantly higher (P<0.001) than the prevalence in 
the whole population of Dalmatia in the south of Croatia (0.75% 
in men).
Conclusion On the basis of these findings, we recommend in-
cluding the newborns from the island of Vis into a screening 
program for G6PD deficiency. Our results indicate that G6PD 
deficiency should be determined for all the island isolates in the 
Mediterranean basin and they warrant further studies.
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Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency is one of the most common inherited 
disorders, with approximately 400 million people 
affected worldwide (1,2). More than 140 differ-
ent mutations of the G6PD gene have been iden-
tified (3). Molecular analysis of the inhabitants 
of the Dalmatian region in the south of Croatia 
identified the G6PD Cosenza (1376 G→C) as 
the most frequent mutation, followed by G6PD 
Mediterranean mutation (563 C→T) (4). All 
individuals with G6PD Mediterranean muta-
tion had concomitant silent C→T transition at 
the position 1311, which is often found in Medi-
terranean basin, but not in Asia (5). Association 
of the factor V Leiden and G6PD deficiency has 
been observed in Dalmatian population (6).
Glucose-6-phosphate dehydrogenase defi-
ciency is unrecognized in most affected individ-
uals. However, it may have a clinical expression 
such as acute acquired hemolytic anemia, chron-
ic nonspherocytic hemolytic anemia, favism, and 
neonatal hyperbilirubinemia (7). Different vari-
ants of the enzyme are found in high frequency 
in African, Mediterranean, and Asian popula-
tions (8). Heterozygote advantage against malar-
ia was found to account for the high frequency of 
distinct alleles in particular populations (9).
Komiža is a small town on the isolated island 
of Vis, in the Adriatic Sea, a part of the Mediter-
ranean basin. Although the prevalence of G6PD 
deficiency has not previously been determined in 
Komiža, there were several cases of favism origi-
nating from Komiža which were treated in our 
hospital. Therefore, we hypothesized that there 
could be a significantly higher incidence of G6PD 
deficiency than in other parts of Dalmatia.
The aim of this study was to determine the 
prevalence of G6PD deficiency in the population 
of Komiža and compare it with the prevalence 
of G6PD deficiency in the whole population of 
Dalmatia. Being an X-linked genetic condition, 
the prevalence of G6PD deficiency in any given 
population is determined by the number of men 
with the deficiency (10).
Participants and methods
Participants
The study included 302 adult men from Komiža 
(median age 47 years; range 5.3-89.8 years) and 
was performed from December 2002 to Feb-
ruary 2003. With the assistance of local gener-
al practitioners, we made a list of the names and 
addresses of all 750 men in Komiža, and assigned 
a number from 1 to 750 to each name. Estimat-
ing that the clinically significant prevalence of 
G6PD deficiency is 5%, and knowing the preva-
lence among men in Dalmatian region, we calcu-
lated that we needed 320 patients to detect a dif-
ference with 90% certainty and a 5% significance 
level. The patients were selected using a random 
number generator. The response rate was 94.4%. 
The Ethical Committee of the Split University 
Hospital approved the study and all studied indi-
viduals signed the informed consent.
Fluorescent spot test
International Committee for Standardization in 
Hematology recommended the fluorescent spot 
test as the most acceptable method for screen-
ing control (11). This method detects the flu-
orescence of NADPH under long-wave (365 
nm) UV light in complete darkness. Reduction 
of NADP to NADPH occurs in the presence of 
G6PD, ie, the rate of NADPH formation is pro-
portional to G6PD activity. Blood used for the 
test was anticoagulated in KT3-EDTA (Becton 
Dickinson, Plymouth, UK) and stored at 4°C 
up to 7 days. Commercially available kits (Cat. 
No. 203, Sigma Diagnostics, Taufkirchen, Ger-
many) were used. Ten microliters of the whole 
blood was incubated with 200 μL of the reagent 
mixture. Spots were made on the filter paper at 
the beginning (zero-time) and 5, 10, and 20 min-
utes after blood incubation with reagent mixture. 
Normal samples fluoresce brightly, whereas defi-
cient samples show little or no fluorescence. The 
results were classified into three groups: bright 
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fluorescence (BF), weak fluorescence (WF), and 
no fluorescence (NF).
Quantitative spectrophotometric method
Enzyme activity was determined by measuring 
the rate of absorbance change at 340 nm, due 
to the reduction of NADP to NADPH when 
a sample was incubated with G6P. Glucose-6-
phosphate dehydrogenase activity was calculated 
in relation to erythrocyte count. Commercially 
available kits (Cat. No. PD 410, Randox Labo-
ratories Ltd, Crumlin, Great Britain) were used. 
Results were interpreted as the percentage of 
normal G6PD activity. Enzyme activity less than 
10% of the normal activity was classified as a se-
vere deficiency, whereas the activity between 10 
and 60% of the normal activity was classified as a 
moderate deficiency.
Statistical analysis
The prevalence of G6PD deficiency in Komiža 
and prevalence among men in the whole region 
were compared by Pearson χ2 test. The result was 
considered significant if probability value was 
equal to or less than 0.01. All data analyses were 
performed using the statistical package SPSS 8.0 
for Windows (SPSS Inc., Chicago, IL, USA).
Results
The fluorescence spot test reading showed that 
266 men (88%) had bright fluorescence in all 
the phases of the test, and according to this, their 
G6PD activity was classified as normal. In 36 
blood samples, which showed weak fluorescence 
and/or no fluorescence spots, enzyme activi-
ties were determined by the spectrophotometric 
UV test. All blood samples with no fluorescence 
at 5 minutes after the beginning of the fluores-
cent spot test were G6PD deficient. Out of 4 
samples with weak fluorescence at 5, 10, and 20 
minutes, 2 were G6PD deficient. All 16 samples 
with weak fluorescence at 5 minutes and bright 
fluorescence at 10 and 20 minutes turned out to 
have normal G6PD activity after the spectropho-
tometric test (Table 1).
Glucose-6-phosphate dehydrogenase defi-
ciency was found in 18 individuals, resulting in 
the prevalence rate of 6.0% (95% CI, 3.3-8.6%). 
Severe G6PD deficiency (lower than 10% of nor-
mal G6PD activity) was found in 14 (78%) indi-
viduals, and the rest of them were suffering from 
moderate deficiency (2 individuals with 18 and     
22% enzyme activity and 2 more with 40 and 
42% enzyme activity).
We compared our results with the rate of 
0.8% (95% CI, 0.3-1.2%) which is the prevalence 
of G6PD deficiency among men in the Dalma-
tian region in the south of Croatia (12). The 
prevalence of G6PD deficiency in Komiža was 
significantly higher (P<0.001, difference 5.2%, 
95% CI, 3.6-6.8%).
Discussion
There are significant differences in the prevalence 
of G6PD deficiency among different nations, 
and even within the same nation, due to migra-
tions, geographical characteristics, and various re-
ligious and cultural factors (13,14). Uneven dis-
tribution of G6PD deficiency, ranging from 1 to 
30% in male infants, was found in Greece (15). 
Table 1. Results of fluorescent spot test for screening of G6PD deficiency (n = 302)
Time of test reading (minutes) No. 
5 10 20 total G6PD-deficient*
No fluorescence no fluorescence no fluorescence  14 14
No fluorescence weak fluorescence weak fluorescence   2  2
Weak fluorescence weak fluorescence weak fluorescence   4  2
Weak fluorescence bright fluorescence bright fluorescence  16  0
Bright fluorescence bright fluorescence bright fluorescence 266  0
*According to the quantitative spectrophotometric method for enzyme activity.
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Population isolation as a major cause for higher 
prevalence of G6PD deficiency was previously 
demonstrated in studies conducted in some parts 
of Greece, Sardinia, and Israel (15-17).
We confirmed our hypothesis that the prev-
alence of G6PD deficiency in Komiža is signifi-
cantly higher than in the entire region (5.96% vs 
0.75%, in men). After obtaining screening test 
results, a letter was sent to all the G6PD deficient 
men and their general practitioners informing 
them about the importance of avoiding precipi-
tating factors for clinical manifestation of G6PD 
deficiency, like fava beans and certain drugs. 
There is a relatively short list of drugs which have 
been shown to cause hemolytic anemia in G6PD 
deficient patients. The risk and severity of hemo-
lysis are usually related to the dose and duration 
of therapy and the presence of additional oxidant 
stress such as infection (9).
An important reason for higher incidence of 
G6PD deficiency in Komiža is the geographical 
position of the island of Vis, which is an isolat-
ed island with a high degree of consanguinity, in-
breeding, and founder effect in population. Also, 
it could be a consequence of Greek colonization 
in the fourth century BC. Isolate island popula-
tions are generally considered to be a suitable set-
ting for efficient and powerful research in genetic 
epidemiology, and a considerable interest has re-
cently been shown for Croatian island isolates. 
Some disorders that appear in Eastern Adriatic 
island populations were found to be related to 
high inbreeding levels (18). Our results suggest 
that rare genetic variants are more frequent in 
human isolate populations than in outbred gen-
eral populations. Therefore, human isolates are 
advantageous for mapping rare genetic variants 
underlying human diseases, including common 
complex diseases. Our findings support the role 
of rare variants in human diseases and the value 
of human isolates in the identification and map-
ping of such variants (19,20).
The Committee on Medical and Public 
Health Research of the European Economic 
Community decided in 1983, at a workshop for 
screening and management of potentially treat-
able genetic metabolic disorders, that screening 
for G6PD deficiency should be performed in 
high-risk populations, ie, Greeks and Sardinians. 
In high-risk populations, it is very important 
to accurately and rapidly diagnose G6PD defi-
ciency early in the neonatal period, before the 
onset of jaundice, and before discharging the 
neonate from hospital (21). Neonates with a se-
vere G6PD deficiency may develop hyperbiliru-
binemia sufficiently severe to cause kernicterus 
and death. Therefore, neonatal jaundice result-
ing from G6PD deficiency requires careful mon-
itoring and earlier beginning of therapy than 
jaundice resulting from other causes (9). Inter-
national Committee for Standardization in He-
matology recommended in 1979 the fluorescent 
spot test as the most acceptable and most reliable 
screening test for G6PD deficiency (11). In com-
parison with other commercially available screen-
ing tests for G6PD deficiency, it was found to 
have 100% sensitivity and 98% specificity (21). 
However, an abnormal screening test should be 
confirmed with a definitive, quantitative test. In 
this study, absence of fluorescence at 5 minutes 
of incubation definitely confirmed G6PD defi-
ciency.
Screening is recommended for infants of 
both sexes (22). In Sardinia, screening for G6PD 
deficiency has been obligatory since 1971, where-
as in Greece, it was incorporated into the exist-
ing national phenylketonuria screening program 
in 1977. Reported prevalence of G6PD deficien-
cy among men was 7.5% in Sardinia and 4.5% 
in Greece. A marked decline in favism was no-
ticed after the beginning of population screen-
ing, which showed that the decision was justified 
(15,16). Screening is not only useful in prevent-
ing favism, but also in the prevention of severe 
neonatal hyperbilirubinemia (23).
With the prevalence of G6PD deficiency 
in Dalmatian region in the south of Croatia be-
ing only 0.75% among men and 0.14% among 
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women, there is no need for a continuous screen-
ing program (12). However, on the basis of our 
findings, we believe that neonatal screening for 
G6PD deficiency, together with a comprehen-
sive education program, should be performed 
for newborns of both sexes on the island of Vis, 
in order to predict those at risk for developing 
favism, jaundice, and severe acute hemolytic at-
tacks. Identification of G6PD-deficient neonates, 
together with the awareness of the condition and 
its danger, will allow a selective approach to their 
hospital discharge and follow-up surveillance. In 
addition, our results indicate that determination 
of G6PD deficiency is necessary for all the island 
isolates in Mediterranean basin and warrants fur-
ther studies.
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